Table 2:
CYFRA 21-1 diagnostic validity efficacy.
| Cutoff 1.8 ng/mL (95% CI) | Cutoff 3.15 ng/mL (95% CI) | Cutoff 3.15 ng/mL without interferencea (95% CI) | |
|---|---|---|---|
| Sensitivity | 90.32% | 80.65% | 79.31% |
| (95% CI) | (73.10–97.47) | (61.94–91.88) | (60.73–90.15) |
| Specificity | 73.71 % | 93.63 % | 95.54% |
| (95% CI) | (67.72–78.95) | (89.66–96.16) | (92.12–97.35) |
| Positive predictive value | 29.79% | 60.98% | 69.70% |
| (95% CI) | (21.02–40.23) | (44.54–75.38) | (52.98–80.32) |
| Negative predictive value | 98.40% | 97.51% | 97.27% |
| (95% CI) | (95.03–99.59) | (94.40–98.98) | (93.87–98.11) |
| Positive likelihood ratio | 3.43 | 12.65 | 17.77 |
| (95% CI) | (2.71–4.35) | (7.64–20.95) | (11.23–24.75) |
| Negative likelihood ratio | 0.13 | 0.21 | 0.22 |
| (95% CI) | (0.04–0.39) | (0.10–0.42) | (0.11–0.43) |
| Youden test | 65.5% | 71.8% | 73.9% |
aWithout interference: without renal and liver disease patients. Renal disease as renal filtrate values (CKD-EPI) < 60 mL/min/1.73 m2 or serum creatinine < 1.3 mg/dL and liver disease as bilirubin total > 4 mg/dL. Results are expressed in percentage (%), and range is expressed in 95% confidence interval (CI).